POCT system for the fecal calprotectin detection in the tele-monitoring of patients with inflammatory bowel disease

Česká verze

Authors: K. Malíčková ^1,2; V. Pešinová ¹; M. Kolář ¹ ; M. Lukáš ^1,2
Authors place of work: Klinické a výzkumné centrum pro idiopatické střevní záněty ISCARE IVF a 1. LF UK, Praha ¹; Ústav lékařské biochemie a laboratorní diagnostiky VFN a 1. LF UK, Praha ²
Published in the journal: Klin. Biochem. Metab., 27, 2019, No. 2, p. 72-77

Summary

Objective: To verify the use of home-based CalproSmart fecal calprotectin (FC) test in the telemonitoring of patients with inflammatory bowel disease (IBD).

Design: Retrospective.

Settings: Clinical Centre ISCARE I.V.F. and 1^st Faculty of Medicine of Charles University, Jankovcova 1569/2c, 170 00 Prague 7, Czech Republic.

Material and Methods: Hundred FC values were compared: first data set was measured by patients using the home-based CalproSmart test based on laminar flow analysis (LFA), and the second data set was obtained by the standard fluoroimmunoassay (FIA) in a clinical laboratory.

Results: Spearman’s correlation coefficient r = 0.895 (p = 0.0004) and weighted Cohen’s kappa 0.835 indicates the good correlation of two data sets measured by different measurement systems.

Conclusion: Home-based FC test CalproSmart is well-suited to qualitative FC analysis in telemonitoring of patients with IBD. It cannot replace standard laboratory FC measurements, but this property is not even required by home-based kit.

Keywords:

fecal calprotectin – inflammatory bowel disease – Telemedicine

Zdroje

1. de Jong, M., van der Meulen-de Jong, A., Romberg-Camps, M., Degens, J., Becx, M., Markus, T. et al. Development and Feasibility Study of a Telemedicine Tool for All Patients with IBD: MyIBDcoach. Inflamm. Bowel. Dis., 2017, 23(4), 485-493

2. de Jong, M. J., van der Meulen-de Jong, A. E., Romberg-Camps, M. J., Becx, M. C., Maljaars, J. P., Cilissen, M. et al. Telemedicine for management of inflammatory bowel disease (myIBDcoach): a pragmatic, multicentre, randomised controlled trial. Lancet., 2017(2), 390(10098), 959-968.

3. Hunter, J., Claridge, A., James, S., Chan, D., Stacey, B., Stroud, M. et al. Improving outpatient services: the Southampton IBD virtual clinic. Postgrad. Med. J., 2012, 88(1042), 487-91.

4. Vinding, K. K., Elsberg, H., Thorkilgaard, T., Belard, E., Pedersen, N., Elkjae, M. et al. Fecal Calprotectin Measured By Patients at Home Using Smartphones--A New Clinical Tool in Monitoring Patients with Inflammatory Bowel Disease. Inflamm. Bowel. Dis., 2016, 22(2), 336-4

5. d’Incà, R., Dal Pont, E., Di Leo, V., Benazzato, L., Martinato, M., Lamboglia, F. et al. Can calprotectin predict relapse risk in inflammatory bowel disease? Am. J Gastroenterol., 2008, 103(8), 2007-14.

6. Bello, C., Roseth, A., Guardiola, J., Reenaers, C., Ruiz-Cerulla, A., Van Kemseke, C. et al. Usability of a home-based test for the measurement of fecal calprotectin in asymptomatic IBD patients. Dig. Liver Dis., 2017, 49(9), 991-996.

7. Wei, S. C., Tung, C. C., Weng, M. T., Wong, J. M. Experience of patients with inflammatory bowel disease in using a home fecal calprotectin test as an objective reported outcome for self-monitoring. Intest. Res., 2018, 16(4), 546-553.

8. Piekkala, M., Alfthan, H., Merras-Salmio, L., Puustinen Wikström, A., Heiskanen, K., Jaakkola, T. et al. Fecal Calprotectin Test Performed at Home: A Prospective Study of Pediatric Patients With Inflammatory Bowel Disease. J Pediatr. Gastroenterol. Nutr., 2018, 66(6), 926-931.

9. Heida, A., Knol, M., Kobold, A. M., Bootsman, J., Dijkstra, G., van Rheenen, P. F. Agreement Between Home-Based Measurement of Stool Calprotectin and ELISA Results for Monitoring Inflammatory Bowel Disease Activity. Clin. Gastroenterol. Hepatol., 2017, 15(11), 1742-1749.

10. Hejl, J., Theede, K., Møllgren, B., Madsen, K. V., Heidari, A., Á Steig, A. et al. Point of care testing of fecal calprotectin as a substitute for routine laboratory analysis. Pract. Lab. Med., 2017, 10, 10-14.